Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 11/20 | 0.50 |
| ▸ | CNR2 | P34972 | 10/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.34 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4563669 | 0.89 | CNR1 (0.46) | CNR1CNR2MEN1KMT2AHSD11B1 | |
| SCHEMBL5141888 | 0.87 | CNR1 (0.53) | CNR1CNR2MEN1KMT2ADPP4 | |
| SCHEMBL4563510 | 0.77 | HSD11B1 (0.40) | CNR1CNR2MEN1KMT2AHSD11B1 | |
| SCHEMBL4563433 | 0.74 | KMT2A (0.50) | CNR1CNR2MEN1KMT2AHSD11B1 | |
| SCHEMBL3683921 | 0.72 | KMT2A (0.52) | CNR1CNR2MEN1KMT2AHSD11B1 | |
| SCHEMBL6106013 | 0.70 | CNR1 (0.80) | CNR1CNR2 | |
| SCHEMBL675859 | 0.70 | CNR1 (0.80) | CNR1CNR2 | |
| SCHEMBL4562967 | 0.70 | CNR1 (0.44) | CNR1CNR2MEN1KMT2A | |
| SCHEMBL6104725 | 0.67 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL6104428 | 0.67 | CNR1 (1.00) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254863-A1 | Use of CBx cannabinoid receptor modulators as potassium channel modulators | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254863-A1 | Use of CBx cannabinoid receptor modulators as potassium channel modulators | CNR2, CNR1, KCNN1 | CNR1 2/4885CNR2 1/4885MEN1 2367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.